APG-3288 in relapsed/refractory blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, multicenter, open-label study of APG-3288 given orally once daily in 28-day cycles. Part 1 aims to find the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) in patients who have failed standard therapy. Part 2 expands to further evaluate safety and pharmacokinetics, with up to 60 patients per indication randomized to 2 or 3 dose cohorts. Eligible cancers include several relapsed/refractory hematologic malignancies such as CLL/SLL, DLBCL (including Richter Transformation), MCL, WM, MZL, and FL. Participants must have had at least two prior therapies and adequate organ function; key exclusions include concurrent anti-cancer therapies other than hormone replacements.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) status ≤ 1 in Part 1 (dose escalation), and ≤ 2 in Part 2 (dose expansion).
* Part 1 (Dose Escalation): histologically or cytologically confirmed diagnosis of R/R CLL/SLL, DLBCL (including Richter Transformation), MCL, WM, MZL, or FL.
* Prior systemic therapy: at least 2 prior lines of systemic therapy (including BTK inhibitor for approved indications) and who have failed or are not eligible for available therapies with established clinical benefit.
* Measurable disease per response criteria specific to the malignant condition.
* Adequate organ and bone marrow function.

Key Exclusion Criteria:

* Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, with the exception of hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogs, agonists required to suppress serum testosterone levels).
* Any investigational therapy within 14 days prior to the first dose of study drug or within 5 half-lives of the respective investigational drug (whichever is shorter).
* Persistent toxicities from prior radiotherapy, targeted therapy, immunotherapy, or chemotherapy agents that have not recovered to Grade \<2 (except for alopecia or vitiligo).
* Symptomatic brain metastases due to tumor involvement of the central nervous system (CNS). Patients with CNS tumors who have been treated, are asymptomatic, and who have discontinued steroids (for the treatment of CNS tumors) for \> 28 days may be enrolled.
* Use of therapeutic-dose anticoagulants or antiplatelet agents. (Use of low-dose anticoagulants to maintain central venous catheter patency is permitted)
* Biological growth factors within 7 days prior to the first dose of study drug.
* Patients who, in the investigator's judgment, have not adequately recovered from prior surgery, or have undergone major surgery within 28 days prior to enrollment, or minor surgery within 14 days prior to enrollment.
* Significant cardiac disease defined as:

  1. New York Heart Association class III or IV cardiac disease, including pre-existing uncontrolled, clinically-significant arrhythmia, congestive heart failure, or cardiomyopathy.
  2. Unstable angina, myocardial infarction, or a coronary revascularization procedure within ≤ 3 months prior to initiation of study treatment.
  3. History of left ventricular ejection fraction \< 50%.
  4. Poorly controlled hypertension, or history of poor compliance with antihypertensive drug regimens.
* Clinically active and uncontrolled symptomatic infection; well-controlled human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection may be considered for enrollment.
* Autoimmune diseases, active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation.
* Concurrent use of QT-prolonging medications or history of torsades de pointes.
* Concurrent malignancy other than the one being treated in this study with the exception of the following: cured malignancy without recurrence within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of any type.
* Any severe and/or uncontrolled medical condition that, in the investigator's opinion, may compromise the individual's safety or the evaluation of study results.
* Prior treatment with: BTK degrader treatment or allogeneic stem cell transplant

Where it's running

• START Los Angele
  Los Angeles, California, United States Recruiting
• Mayo Clinic
  Jacksonville, Florida, United States Recruiting
• START Midwest
  Grand Rapids, Michigan, United States Recruiting
• START New Jersey
  East Brunswick, New Jersey, United States Recruiting
• Henan Cancer Hospital
  Zhengzhou, Henan, China Recruiting
• The University of TX MD Anderson Cancer Center
  Houston, Texas, United States Not yet recruiting

Study contacts

• Principal investigator: Keshu Zhou, M.D.,Ph.D. — Henan Cancer Hospital
• Study coordinator: Yifan Zhai, M.D., Ph.D.
• Email: Yzhai@ascentage.com
• Phone: 18998334688

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hypofractionation Radiotherapy + Glofitamab in Relapsed/Refractory DLBCL with High Tumor Burden

  This study tests whether giving hypofractionated radiotherapy together with glofitamab helps people with relapsed/refractory DLBCL and large tumors see better responses.

  Recruiting Phase 2 Huazhong University of Science and Technology · Wuhan, Hubei · NCT06867536

• How olverembatinib is processed in people with liver impairment

  This test gives a single 20 mg dose of olverembatinib to people with different levels of chronic liver impairment and matched healthy volunteers to see how the drug is absorbed, distributed, metabolized, and cleared.

  Recruiting Phase 1 Ascentage Pharma Group Inc. · Suzhou, Jiangsu · NCT07282093

• Evaluating APG-2449 for treating advanced ovarian cancer and solid tumors

  This study is testing a new drug called APG-2449 to see if it can safely help people with advanced ovarian cancer and other solid tumors, both on its own and when combined with another treatment.

  Recruiting Phase 1 Ascentage Pharma Group Inc. · Guangzhou, Guangdong · NCT06687070

• Combining Lisaftoclax with Azacitidine for treating higher-risk Myelodysplastic Syndrome

  This study is testing if combining Lisaftoclax with azacitidine can help people newly diagnosed with higher-risk Myelodysplastic Syndrome live longer compared to just using azacitidine with a placebo.

  Recruiting at 143 sites Phase 3 Ascentage Pharma Group Inc. · Birmingham, Alabama and 154 other locations · NCT06641414

• Olverembatinib for treating SDH-deficient GIST

  This study is testing if a new medication called olverembatinib can help people with a specific type of gastrointestinal tumor feel better after they’ve already tried one other treatment.

  Recruiting Phase 3 Ascentage Pharma Group Inc. · Guangzhou, Guangdong · NCT06640361

• Treatment of Chronic Myeloid Leukemia with Olverembatinib

  This study is testing if a new drug called olverembatinib can help people with chronic myeloid leukemia feel better compared to an existing treatment, and it looks at two groups of patients based on a specific genetic mutation.

  Recruiting at 135 sites Phase 3 Ascentage Pharma Group Inc. · Birmingham, Alabama and 162 other locations · NCT06423911

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.